This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Ataxia  • Neurogenetics  • Tremor  • Neurology, Other  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

An Aging Face of the Fragile X Gene

Khaled Amiri, PhD; Randi J. Hagerman, MD; Paul J. Hagerman, MD, PhD

Arch Neurol. 2008;65(1):19-25.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Fragile X–associated tremor/ataxia syndrome (FXTAS) is a late-adult–onset neurodegenerative disorder affecting primarily male (and occasionally female) carriers of a premutation expansion (55-200 CGG repeats) of the fragile X mental retardation 1 gene (FMR1). FXTAS is principally characterized as a movement disorder with progressive intention tremor and gait ataxia, with more variable associated features of parkinsonism, dysautonomia, peripheral neuropathy, and dementia. The pathogenic basis of FXTAS is overexpression of the "toxic" expanded CGG repeat FMR1 RNA, which leads to neural cell dysregulation, formation of intranuclear inclusions in neurons and astrocytes, and disruption of the nuclear lamin architecture. By contrast, larger CGG repeat expansions (> 200 CGG repeats, full mutation) generally result in FMR1 silencing and absence of FMR1 RNA and protein (FMRP). The lack of FMRP is the pathogenic basis of the developmental disorder fragile X syndrome, the . . . [Full Text of this Article]

CLINICAL PHENOTYPE AND SPECTRUM OF INVOLVEMENT IN FXTAS

EPIDEMIOLOGY

NEUROPATHOLOGY

MOLECULAR PATHOGENESIS

TREATMENT OPTIONS

AUTHOR INFORMATION

Author Affiliations: Department of Biology, College of Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates (Dr Amiri); Departments of Pediatrics (Dr R. J. Hagerman) and Biochemistry and Molecular Medicine (Dr P. J. Hagerman) and the M.I.N.D. Institute (Drs R. J. Hagerman and P. J. Hagerman), School of Medicine, University of California, Davis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fibroblast phenotype in male carriers of FMR1 premutation alleles
Garcia-Arocena et al.
Hum Mol Genet 2009;0:ddp497v2-ddp497.
ABSTRACT | FULL TEXT  

Translation of the FMR1 mRNA is not influenced by AGG interruptions
Ludwig et al.
Nucleic Acids Res 2009;37:6896-6904.
ABSTRACT | FULL TEXT  

Screening for Expanded Alleles of the FMR1 Gene in Blood Spots from Newborn Males in a Spanish Population
Fernandez-Carvajal et al.
J. Mol. Diagn. 2009;11:324-329.
ABSTRACT | FULL TEXT  

A Quantitative ELISA Assay for the Fragile X Mental Retardation 1 Protein
Iwahashi et al.
J. Mol. Diagn. 2009;11:281-289.
ABSTRACT | FULL TEXT  

The quadruplex r(CGG)n destabilizing cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of fragile X premutation mRNA
Ofer et al.
Nucleic Acids Res 2009;37:2712-2722.
ABSTRACT | FULL TEXT  

Chromatin Remodeling in the Noncoding Repeat Expansion Diseases
Kumari and Usdin
J. Biol. Chem. 2009;284:7413-7417.
ABSTRACT | FULL TEXT  

The fragile X prevalence paradox
Hagerman
J. Med. Genet. 2008;45:498-499.
FULL TEXT